Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Third Harmonic Bio (THRD) Competitors

Third Harmonic Bio logo

THRD vs. ZBIO, BGM, EYPT, PGEN, MNMD, SEPN, CRMD, DNA, FTRE, and KURA

Should you be buying Third Harmonic Bio stock or one of its competitors? The main competitors of Third Harmonic Bio include Zenas BioPharma (ZBIO), BGM Group (BGM), Eyepoint Pharmaceuticals (EYPT), Precigen (PGEN), Mind Medicine (MindMed) (MNMD), Septerna (SEPN), CorMedix (CRMD), Ginkgo Bioworks (DNA), Fortrea (FTRE), and Kura Oncology (KURA). These companies are all part of the "med - biomed/gene" industry.

Third Harmonic Bio vs. Its Competitors

Zenas BioPharma (NASDAQ:ZBIO) and Third Harmonic Bio (NASDAQ:THRD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Third Harmonic Bio's return on equity of -19.27% beat Zenas BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Zenas BioPharmaN/A -59.21% -50.56%
Third Harmonic Bio N/A -19.27%-18.67%

In the previous week, Zenas BioPharma had 49 more articles in the media than Third Harmonic Bio. MarketBeat recorded 49 mentions for Zenas BioPharma and 0 mentions for Third Harmonic Bio. Zenas BioPharma's average media sentiment score of 0.46 beat Third Harmonic Bio's score of 0.00 indicating that Zenas BioPharma is being referred to more favorably in the media.

Company Overall Sentiment
Zenas BioPharma Neutral
Third Harmonic Bio Neutral

Third Harmonic Bio has lower revenue, but higher earnings than Zenas BioPharma. Third Harmonic Bio is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zenas BioPharma$5M223.52-$156.99M-$3.55-7.48
Third Harmonic BioN/AN/A-$45.47M-$0.62-8.68

94.0% of Third Harmonic Bio shares are owned by institutional investors. 16.5% of Zenas BioPharma shares are owned by company insiders. Comparatively, 7.8% of Third Harmonic Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Zenas BioPharma presently has a consensus target price of $38.33, suggesting a potential upside of 44.44%. Third Harmonic Bio has a consensus target price of $5.00, suggesting a potential downside of 7.06%. Given Zenas BioPharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Zenas BioPharma is more favorable than Third Harmonic Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zenas BioPharma
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Third Harmonic Bio
0 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Zenas BioPharma beats Third Harmonic Bio on 7 of the 12 factors compared between the two stocks.

Get Third Harmonic Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for THRD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding THRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

THRD vs. The Competition

MetricThird Harmonic BioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$242.80M$3.33B$6.04B$10.46B
Dividend YieldN/A2.31%5.73%4.79%
P/E Ratio-4.3722.2285.3127.07
Price / SalesN/A445.29591.31190.92
Price / CashN/A44.9825.7330.17
Price / Book0.8510.3812.666.69
Net Income-$45.47M-$52.31M$3.31B$276.03M

Third Harmonic Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
THRD
Third Harmonic Bio
N/A$5.38
flat
$5.00
-7.1%
N/A$242.80MN/A-4.37N/A
ZBIO
Zenas BioPharma
2.2265 of 5 stars
$20.85
-9.5%
$36.67
+75.9%
N/A$969.80M$5M-5.87N/AAnalyst Revision
BGM
BGM Group
0.5591 of 5 stars
$9.69
-2.1%
N/A+29.9%$962.98M$25.10M0.00298Gap Down
EYPT
Eyepoint Pharmaceuticals
1.4683 of 5 stars
$13.25
-2.7%
$26.86
+102.7%
+53.7%$938.79M$43.27M-4.94120
PGEN
Precigen
4.4718 of 5 stars
$3.31
+5.4%
$8.25
+149.2%
+247.2%$935.64M$3.92M-7.88190
MNMD
Mind Medicine (MindMed)
2.4622 of 5 stars
$11.97
-2.0%
$26.50
+121.4%
+118.3%$929.79MN/A-7.8240Analyst Forecast
Gap Up
SEPN
Septerna
0.8456 of 5 stars
$21.01
+1.0%
$26.75
+27.3%
N/A$927.37M$1.08M-2.08N/A
CRMD
CorMedix
2.8246 of 5 stars
$11.09
-4.1%
$18.00
+62.3%
+6.0%$902.36M$43.47M14.7930Analyst Downgrade
DNA
Ginkgo Bioworks
1.1778 of 5 stars
$14.81
-0.4%
$9.00
-39.2%
+84.4%$880.30M$230.82M-2.53640Gap Up
FTRE
Fortrea
3.2051 of 5 stars
$9.31
-2.9%
$11.72
+25.9%
-48.9%$870.77M$2.70B-0.8215,500Analyst Downgrade
Gap Up
KURA
Kura Oncology
4.0632 of 5 stars
$9.43
-3.8%
$24.10
+155.6%
-47.0%$850.61M$53.88M-4.17130

Related Companies and Tools


This page (NASDAQ:THRD) was last updated on 10/13/2025 by MarketBeat.com Staff
From Our Partners